Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's SFDA To Set Up System For New Drug Application, Approval And Appraisal

This article was originally published in PharmAsia News

Executive Summary

China's State FDA has released 44 drug databases to publicize all China-marketed drugs on its official website (http://www.sda.gov.cn/). The public can check 980,000 drug items, as well as medical devices and health products, for authenticity and effectiveness/functions, before making a purchase. The agency is also building the database for cosmetic products. Information on drug appraisal is now more transparent: companies that submit new drug applications can enquire online about the status during the drugs' prelaunch safety and efficacy appraisal process at the drug evaluation center website (http://www.cde.org.cn/). The major steps of new drug application, appraisal and approval have been fully divided to prevent unrestricted power that may lead to corruption and safety lapses. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066849

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel